Showing 6761-6770 of 9735 results for "".
- Aclaris Therapeutics, Inc. Appoints Brett Fair as Senior Vice President of Commercial Operationshttps://practicaldermatology.com/news/aclaris-therapeutics-inc-appoints-brett-fair-as-senior-vice-president-of-commercial-operations/2458784/Aclaris Therapeutics, Inc. has appointed Brett Fair as Senior Vice President of Commercial Operations. Mr. Fair brings more than 18 years of pharmaceutical commercialization and business
- AADA Supports New Bill to Protect Senior Access to Dermatologic Carehttps://practicaldermatology.com/news/aada-supports-new-bill-to-protect-senior-access-to-dermatologic-care/2458781/The American Academy of Dermatology Association (AADA) supports the Medicare Advantage Bill of Rights Act, introduced by Sen. Sherrod Brown (D-Oh.) and Rep. Rosa DeLauro (D-Conn.). If passed, the legislation would ensure that patients will have adequate physician networks in their Medicare Advant
- Safe, Inexpensive Chemical Found to Reverse Symptoms of Progeria in Human Cellshttps://practicaldermatology.com/news/safe-inexpensive-chemical-found-to-reverse-symptoms-of-progeria-in-human-cells/2458787/New work from the University of Maryland suggests that a common, inexpensive and safe chemical called methylene blue could be used to treat progeria—and possibly the symptoms of normal aging as well. A new study shows for the first time that small doses of methylene blue can almost complete
- AAD Issues Statement on Skin Cancer Screeninghttps://practicaldermatology.com/news/aad-issue-statement-on-skin-cancer-screening/2458789/Mark G. Lebwohl, MD, FAAD, President, American Academy of Dermatology issued the following statement on skin cancer screenings: “The American Academy of Dermatology believes that early detection is vital in the fight against skin cancer, the most common cancer in the United States.
- Cosmetic Surgery Forum Wraps Seventh Successful Yearhttps://practicaldermatology.com/news/cosmetic-surgery-forum-wraps-seventh-successful-year/2458791/Covering topics from the appropriate use of permanent fillers to the role of spirituality in practice, the seventh annual Cosmetic Surgery Forum (CSF) brought together experts from multiple specialties at the Aria in Las Vegas this month. The three-day program included guidance on practice manage
- Review Does Not Support Monthly Lab Testing for Oral Isotretinoin Use for Acnehttps://practicaldermatology.com/news/review-does-not-support-monthly-lab-testing-for-oral-isotretinoin-use-for-acne/2458793/A review of medical literature does not support monthly laboratory testing for all patients who are using standard doses of the acne medication isotretinoin, according to an article published online by JAMA Dermatology</
- Data: Acne Sufferers Lack Understanding About Use of Antibiotics to Treat Acne and Potential Resistancehttps://practicaldermatology.com/news/data-acne-sufferers-lack-understanding-about-use-of-antibiotics-to-treat-acne-and-potential-resistance/2458797/A recent survey sponsored by Galderma Laboratories, L.P., inclusive of 809 acne sufferers (ages 17-40 years) and 210 parents of acne sufferers (child, aged 9-17 years), found that despite the risk of antibiotic resistance and potential side effects:
- Study Finds Increasing Prices for Prescription Dermatology Drugs Since 2009https://practicaldermatology.com/news/study-finds-increasing-prices-for-prescription-dermatology-drugs-since-2009/2458800/A recent study published in JAMA Dermatology found that the price of prescription dermatologic drugs rose considerably from 2009 to 2015, with the vast majority of price increases occurring after 2011. In an effo
- Brickell Secures Rights to a Novel Class of RORγ Inhibitors for Psoriasis and Other Autoimmune Diseaseshttps://practicaldermatology.com/news/brickell-biotech-secures-rights-to-a-novel-class-of-ror-inhibitors-for-psoriasis-and-other-autoimmune-diseases/2458801/Brickell Biotech, Inc. has secured the exclusive world-wide rights to a series of novel retinoic acid–related orphan nuclear receptor gamma (RORy) inhibitors from Orca Pharmaceuticals (Orca) and New York University (NYU). This chemical series is based on intellectual property emerg
- Almirall Acquires Veltin® and Altabax® from Stiefel, a GSK Companyhttps://practicaldermatology.com/news/almirall-acquires-veltin-and-altabax-from-stiefel-a-gsk-company/2458802/Almirall has acquired the rights to Veltin® and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino® and an undisclosed cash payment.